Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Shopify

Vertex stock could take off if a gene-editing therapy obtains approval this year. Shopify's stock has taken a beating, but it still has plenty of growth opportunities.

Got $5,000? Buy and Hold These Fast-Growing Stocks for Years

Intellia Therapeutics

Precigen

Many investors look for growth opportunities wherever they can find them. If that describes you, then there are some high-growth biotech stocks that could present an opportunity.

3 High-Growth Biotech Stocks Poised for Success in 2023

Dollar General

Johnson & Johnson

Dollar General is arguably the ultimate recession-proof stock. Johnson & Johnson is a favorite safe-haven stock for investors during economic downturns.

The Fed Thinks a Recession Is More Likely: Here Are 3 Great Stocks to Buy Now

Altria

Tesla

Buffett recently gave an intriguing hypothetical scenario that underscores Apple's customer loyalty. Other stocks could pass the threshold mentioned by Buffett -- some quite easily.

Which Stocks Pass Warren Buffett's $10,000 Test?

MercadoLibre

Trade Desk

MercadoLibre combines e-commerce, fintech, and emerging market opportunities in one fell swoop. The Trade Desk has a massive opportunity with the rapid growth in connected TV.

Prediction: These Will Be 3 of the Biggest Monster Stocks of the Decade

CRISPR Therapeutics

Vertex Pharmaceuticals has a relatively safe top line, and more growth on the way. CRISPR Therapeutics is on track to start realizing revenue growth like wild.

2 Nasdaq Growth Stocks That Are Screaming Buys in April

ImmunoGen

Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.

Could This Move Make Vertex's Next Blockbuster Even Bigger?

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the “Vertex Pharmaceuticals First Quarter 2023 Earnings Call.

Vertex to Announce First Quarter 2023 Financial Results on May 1

Amazon

Brookfield Renewable Partners

Devon Energy

Two of these stocks have technology ties, one in cloud hosting and the other in adtech. Two are in the energy sector and offer great dividends plus solid growth prospects.

My 5 Top Stocks to Buy in April

Upstart Holdings

Even another market downturn could present opportunities for long-term investors. Vertex Pharmaceuticals isn't slowing down, but more growth opportunities could be on the near horizon.

2 Winning Stocks That Could Turn $10,000 into $50,000 by 2030

Novo Nordisk

Pfizer

Novo Nordisk has exceptional growth prospects with its diabetes and obesity drugs. Pfizer isn't getting the respect it deserves.

3 No-Brainer Stocks to Buy in a New Bull Market

Datadog

Okta

Pubmatic

Although all three major U.S. stock indexes fell into a bear market in 2022, the growth-driven Nasdaq Composite was the worst performer. For long-term investors, a bear market is a blessing in disguise.

Nasdaq Bear Market: 5 Astonishing Growth Stocks You'll Regret Not Buying on the Dip

Cardinal Health

Intuitive Surgical

Insulet

Merck

Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.

5 S&P 500 Stocks Showing Strength As Recession Fears Rise

Growth in sales of their cystic fibrosis portfolio that they are pushing to expand further. Stable financial position with low debt and good cash reserves.

Vertex Pharmaceuticals: A Promising Portfolio After A Year Of Growth

The healthcare industry is full of intriguing and resilient investment opportunities. Intuitive Surgical has unrivaled market leadership and many sources of revenue.

2 Once-in-a-Decade Buying Opportunities in a Growth Stock Bear Market

Lululemon Athletica

Healthcare and athleisure are massive and fast-growing industries, and even a recession can't slow them down for long. Vertex Pharmaceuticals could be in the early days of its growth story.

A Bull Market Is Coming: 2 Unstoppable Growth Stocks to Scoop Up Right Now

Airbnb

Growth stocks aren't all facing struggles right now. Vertex is boosting profits, and its product pipeline is more promising than ever.

2 Smartest Growth Stocks to Buy Without Hesitation Right Now

The volatile market doesn't mean investors need to stay inactive on the sidelines. Vertex Pharmaceuticals is gearing up for another product launch in the not-too-distant future.

2 Top Stocks to Buy Before the Next Nasdaq Bull Market

Vertex Pharmaceuticals is a top seller of cystic fibrosis treatments -- but it's about to expand into a new growth area. Vertex and partner CRISPR Therapeutics have just completed the submission of their blood disorders treatment candidate to U.S. regulators.

Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Alphabet

Alphabet's valuation and long-term prospects look really attractive. The Trade Desk has plenty of room to run with the explosive growth of connected TV.

A Nasdaq Bull Market Could Begin in April: 3 Top Stocks to Buy Now

Kinder Morgan

Rivian Automotive

Warner Bros Discovery Inc

Zscaler

The sell-off in growth stocks has been brutal. Bridging the gap between investor expectations and reality can lead to sizable stock rebounds.

5 Top Stocks for April

Vertex is tapping into its partner's technology to develop potential therapies for type 1 diabetes. One of the biotech's existing treatments in this area has shown promise in clinical trials.

This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for Investors

A turbulent market can be tough for investors, but great companies remain ripe for the picking. Intuitive Surgical has seen a slowdown in procedure volumes recently, but it's for short-term reasons.

Have $2,000? 2 Exceptional Stocks to Buy In a Bear Market

Novartis

Despite an unfavorable macro environment in 2022, some stocks did manage to churn out respectable gains last year. Novartis and Vertex Pharmaceuticals were two of last year's biggest winners within the large-cap space.

News for Vertex Pharmaceuticals Stock (VRTX)